Pentagon contract could send this $2 AI stock soaring

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

PMN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 18.50%

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$0.00

ProMIS Neurosciences Insider Trading History Chart

ProMIS Neurosciences Share Price & Price History

C^$0.00

+0.30 (1.20%)

As of 07/22/2023 12:59 AM ET

Days: 30 | 90 | 365

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

ProMIS Neurosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2022	Eugene Warren Williams	Director	Buy	1,000	C$6.32	C$6,324.00	159,764
12/12/2022	Eugene Warren Williams	Director	Buy	1,000	C$6.90	C$6,902.00	158,764
12/7/2022	Eugene Warren Williams	Director	Buy	1,000	C$7.47	C$7,466.40	157,764
12/2/2022	Eugene Warren Williams	Director	Buy	1,000	C$8.13	C$8,132.80	156,764
8/16/2022	Patrick D. Kirwin	Director	Buy	4,000	C$7.65	C$30,600.00	41,982
7/11/2022	Eugene Warren Williams	Director	Buy	1,000	C$9.80	C$9,800.00	155,764
6/30/2022	Eugene Warren Williams	Director	Buy	200	C$8.31	C$1,662.63	152,764
6/30/2022	Neil Cashman	Senior Officer	Buy	609	C$8.19	C$4,984.67	102,661
6/27/2022	Eugene Warren Williams	Director	Buy	5,000	C$0.14	C$689.00	8,858,816
6/23/2022	Eugene Warren Williams	Director	Buy	500,000	C$0.13	C$64,285.00	8,503,816
6/23/2022	Neil Cashman	Senior Officer	Buy	38,500	C$0.12	C$4,427.50	6,069,144
12/3/2021	Patrick D. Kirwin	Director	Sell	31,500	C$0.15	C$4,567.50	1,641,450

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

See how you can invest alongside him

SEC Filings (Institutional Ownership Changes) for ProMIS Neurosciences (TSE:PMN)

2.20% of ProMIS Neurosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Today's Range

Now: N/A

50 Day Range

MA: C$6.00

C$6.00

52 Week Range

Now: N/A

Volume

19,701 shs

Average Volume

3,327 shs

Market Capitalization

C$51.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Who are the company insiders with the largest holdings of ProMIS Neurosciences?: ProMIS Neurosciences' top insider shareholders include:
Eugene Warren Williams (Director)
Neil Cashman (Senior Officer)
Patrick D Kirwin (Director)
Learn More about top insider investors at ProMIS Neurosciences.